Introduction
Down's syndrome, also known as trisomy 21, occurring at an incidence of approximately one in 1000 live births, is the most frequent survivable congenital chromosomal abnormality and the most frequent cause of congenital intellectual disability in humans [1] [2] [3] . Although the clinical presentation of Down's syndrome is complex and variable, characteristic features such as progressive mental deterioration, increased risk for autoimmune disease, and early-onset Alzheimer's disease support the hypothesis that Down's syndrome is associated with premature aging and abnormalities in the innate immune response [2] [3] [4] [5] [6] [7] . Early genetic and bioinformatics analyses suggested that much of the developmental pathology of Down's syndrome can be attributed to the 'gene dosage' effect of the extra chromosome 21, resulting from the 50% increase in expression of the B300 genes encoded on chromosome 21, that leads to an imbalance in critical gene expression, which in turn promotes the Down's syndrome phenotype [2, 3] . More recent genetic evidence suggests that the Down's syndrome phenotype is most likely multigenetic, and only a specific subset of the 300 or so trisomic genes, interacting with other disomic genes, mediates disease onset [4, 5] . Recent analysis has shown that human chromosome 21 encodes a specific subset of micro-RNAs (miRNAs) including let-7c, miRNA-99a, miRNA-125b-2, miRNA-155b, and miRNA-802 ( [6] ; unpublished data). The major mode of action of these small, noncoding RNAs is to interact, through base-pair complementarity, with the 3 0untranslated region (3 0 -UTR) of their target mRNAs, and in doing so decrease the expression of that particular target mRNA [7] [8] [9] [10] [11] [12] . In fact, ribosome profiling has shown that upregulated miRNAs act predominantly to decrease their target mRNA levels, and miRNA-mediated destabilization of mRNAs is the main reason for reduction in gene expression [10] . Of the approximately 1250 human miRNAs identified currently, individual human tissues seem to use only a small subset of this total number; for example, the human neocortex probably utilizes less than 40 major miRNAs [8, 11, 12] . Interestingly, physiologically relevant stressors such as viruses, cytokines, and oxidative stress are strong inducers of miRNA and of ensuing effects on mRNA speciation, and again these effects are significantly cell and tissue specific, even within related cell types in the same tissue [8, 9, [11] [12] [13] [14] [15] . In these experiments we analyzed for trisomy 21-upregulated miRNAs associated with Down's syndrome, and found that of the five miRNAs located on chromosome 21 only miRNA-155 was significantly upregulated in the brain and in immunogenic organs. A bioinformatics-predicted target of miRNA-155 and immune system repressors, complement factor H (CFH), was found to be downregulated in Down's syndrome brain, liver, and spleen. In primary cocultures of human neuronal-glial (HNG) cells, stress-induced miRNA-155-mediated downregulation of CFH was found to be reversible using anti-miRNA (AM)-155. The results suggest that a miRNA-155-mediated downregulation of CFH may be a consequence of trisomy 21 and may explain altered immune processes that contribute to the Down's syndrome phenotype.
Materials and methods
Reagents, Down's syndrome tissues, and human neuronal-glial cells Reagents used in these experiments were obtained from commercial suppliers and were used without further purification [15] [16] [17] [18] [19] . Human recombinant TNFa (T6674; Sigma-Aldrich Chemical Company, St Louis, Missouri, USA) was used as described previously [15] . Down's syndrome and age-matched control human brain, spleen, and liver tissues were obtained from brain and tissue repositories, including the Institute for Memory Impairments and Neurological Disorders and the University of California at Irvine. Tissues were analyzed for total miRNA and CFH abundance using western analysis [8, 9, [12] [13] [14] . All Down's syndrome patients were adults. All brain tissues were from the temporal lobe, all were epilepsy free, and all had been trisomy 21-genotyped previously [20] . The mean (± 1 SD) age of the control brain group (N = 8; all women) was 48.1 ± 8.2 years and the mean postmortem interval (PMI; death to brain freezing interval) was 2.8 h. The mean age of the Down's syndrome group (N = 5; five women) was 46.7 ± 11.5 years and mean PMI was 3.1 h. There were no significant differences in the age, sex, or PMI between the Down's syndrome and control tissue groups.
Total RNA and protein extraction and quality control Total RNA and proteins were simultaneously isolated using TRIzol (Invitrogen, Carlsbad, California, USA) [9, [12] [13] [14] . RNA quality was assessed using an Agilent Bioanalyzer 2100 (Lucent Technologies, Santa Clara, California, USA/ Caliper Technologies, Mountainview, California, USA) [15, 16] . Typically, 1 ul of the total RNA sample was loaded onto the 6000 Nano Labchip (Caliper Technologies) and analyzed for quality control; RNA integrity number values were typically 9.0 [14] [15] [16] [17] [18] . Protein concentrations were determined using a dotMETRIC microassay (sensitivity 0.3 ng protein/ml; Chemicon-Millipore, Billerica, Massachusetts, USA) [12, 18] . miRNA array, northern analysis reverse transcriptasepolymerase chain reaction, and anti-miRNA-155 miRNA labeling, hybridization, miRNA arrays, northern dot blot analysis, and RT-PCR analysis were carried out as described previously [8, 9, [12] [13] [14] [15] [16] [17] [18] [19] . AM, as locked nucleic acid oligonucleotides, to let-7c, miRNA-99a, miRNA-125b, miRNA-802s, miRNA-155b (AM-155; 5 0 -aattacgattagcactatcccca-3 0 ), and a scrambled control AM-155 (AM-155sc; 5 0 -ttaacattagacgatatcccacc-3 0 ; containing the same nucleotide sequence as AM-155, but in random nucleotide order) were purchased from Applied Biosystems/ Ambion (Austin, Texas, USA) or Exiqon Inc. (Woburn, Massachusetts, USA) [11, 16] .
Western blot analysis of complement factor H and b-actin in Down's syndrome tissues
Western immunoblotting was carried out for quantification of CFH and b-actin protein in control and Down's syndrome tissues using human-specific primary antibodies directed against the control protein marker b-actin (3598-100; Sigma-Aldrich Chemical Company) or human CFH (H-7; sc-166613H-5; sc-166608; Santa Cruz Biotechnologies, Santa Cruz, California, USA) [15] [16] [17] 19, 21] .
Statistical analysis and data interpretation
All miRNA array, northern dot blot, and RT-PCR data were analyzed as previously described [14, 16] . Statistical procedures for measuring protein (enzyme-linked immunosorbent assay and western blotting) abundance were analyzed using a two-way factorial analysis of variance (P) using programs and procedures in the SAS language (Statistical Analysis Institute, Cary, North Carolina, USA) [14] [15] [16] . Only P values of less than 0.05 (analysis of variance) were considered statistically significant. Figures were generated using Excel 2008 (Microsoft, Redmond, Washington, USA) and Photoshop CS2 ver. 9.0.2 (Adobe, San Jose, California, USA).
Results

Upregulation of miRNA-155 in Down's syndrome
The miRNA array, RT-PCR, and northern dot blot analysis ( Fig. 1 , data not shown) did not detect miRNA-802. The abundance of the four detectable chromosome 21-encoded miRNAs was found to be in the ratio of let-7c : miRNA-99a : miRNA-125b : miRNA-155 of 20 : 8 : 3 : 1 when compared with an unchanging control miRNA-183 or 5S RNA in the same sample. However, only miRNA-155 was found to be significantly upregulated in Down's syndrome tissues and showed increases of 3.4-fold, 2.7-fold, and 2.9-fold over age-matched controls in the brain, liver, and spleen, respectively ( Fig. 1 ). Increases in miRNA-155 are therefore greater than could be explained by the 1.5-fold increases that the extra chromosome 21 gene dosage effects would be expected to contribute (Fig. 1) .
Bioinformatics, miRNA-155 and CFH abundance, and anti-miRNA-155 effects A bioinformatics search for miRNA-155 mRNA targets involved in immune signaling using the miRNA target prediction algorithms (http://www.mirBASE.com and http:// www.targetscan.org) indicated that the miRNA-155-CFH mRNA-3 0 UTR interaction is highly stable, with a free energy of association (E A ) of -26.1 kcal/mol (Fig. 2) . This prompted us to analyze CFH protein abundance in the Down's syndrome tissues. The results indicate significant decreases to 0.35-fold, 0.51-fold, and 0.45-fold of controls in the brain, liver, and spleen, respectively (Fig. 3) .
To examine the relationship between miRNA-155 upregulation and CFH downregulation we next analyzed the miRNA-155 and CFH in Down's syndrome Li et al. 169 effects of cytokine TNFa-stressed HNG cells. These 2week-old co-cultures contain approximately 60% neurons and 40% glia whose growth and response to cytokine stress have been extensively described [9, [12] [13] [14] [15] [16] [17] [18] . We found that TNFa-stressed HNG cells exhibited a significant miRNA-155 upregulation coupled with CFH downregulation, an effect that was quenched using AM-155 ( Fig. 4) . Neither anti-let-7c nor AM-99a, AM-125b, or AM-155sc showed any such quenching effects (data not shown).
Discussion
Genetically, 95% of individuals with Down's syndrome have one complete extra copy of chromosome 21 and the remaining 5% have a partial duplication of this smallest, 47-million-base pair chromosome [1] [2] [3] [4] [5] . Down's syndrome displays a complex and variable spectrum of pathological and clinical features, including systemic oxidative stress and inflammation, particularly in the brain and in tissues involved in immune response [4] [5] [6] [7] 20, 22, 23] . Morphological and functional deficits in Down's syndrome brains include aberrations in inflammatory and immunological markers, altered neuronal cytoarchitecture, and synaptogenesis [1] [2] [3] [4] [5] [6] . In humans, miRNA-155 is recognized as a central regulator of the innate immune system and is involved in various lymphoproliferative disorders [6, 7, 16, [20] [21] [22] [23] . In this study, Down's syndrome brain, liver, and spleen exhibited selective increases in miRNA-155; no other chromosome 21-encoded miRNAs attained this significance (Fig. 1 ). Note that normal human liver and spleen contain among the highest abundance of CFH of any solid tissues. These tissues further exhibit elevated miRNA-155 and reductions of CFH in Down's syndrome tissues (Figs 1 and 3) . Through genetic and bioinformatics analyses we found an exceptionally strong binding site for miRNA-155 in the CFH mRNA 3 0 -UTR. In this interaction 17 of 23 (74%) nucleotides are perfectly complementary and four of 23 (17%) are partially complementary, yielding an extremely stable miRNA-mRNA hybrid (Fig. 2) . In stressed HNG cells, increases in miRNA-155 correlated with CFH downregulation, and an AM-155 was shown to quench miRNA-155 abundance and restore CFH back to homeostatic levels ( Fig. 4) .
CFH (also known as adrenomedullin-binding protein-1, b1H globulin, C3b inactivator-accelerator, and H factor-1) is a crucial member of the regulator of complement activation group of proteins encoded at the chromosome-1q21 regulator of complement activation gene locus. This soluble 155 kDa glycoprotein is normally secreted by the liver and reaches blood plasma concentrations of 500-800 mg/ml in the systemic circulation [16, 21] . CFH is the second most abundant plasma protein, after serum albumin, and normally performs a systemic 'sentinel' function against spontaneous immune activation [21, 22] . It is not clear whether CFH is permeable to the blood-brain barrier. The brain may have an independent CFH supply secreted by neurons, astroglia, and microglial cells [11, 15] . CFH normally acts as a specific inhibitor of the C3 to C3b transition in the complement pathway. Systemic CFH deficits are conducive to excessive and pathogenic complement miRNA-155 is upregulated in Down's syndrome brain, liver, and spleen using miRNA array and RT-PCR analyses. Typical miRNA array results in the brain are shown in (a) and of an RT-PCR analysis in the bar graph format in (b). In (a), the arrow points to an increased miRNA-155 signal (position 3f) [8] [9] [10] [11] [12] . Other chromosome 21-encoded miRNAs, let-7c (position 1a), miRNA-99a (position 2d), miRNA-125b (position 2i), were detected but showed no significant upregulation over what would be expected from gene dosage effects alone (B1.15-1.5-fold increases; other positions in (a) are non-chromosome 21 brainabundant miRNAs) [8, 11, 12] . In these experiments, miRNA-802 (position 4l) was not detected. An unchanging control miRNA-183 (loaded in triplicate) is at positions 1g, 1i, and 1k. Northern dot blot analysis showed similar miRNA expression trends (data not shown) [11, 16] . (b) miRNA-155 abundance in Down's (DS) syndrome brain, liver, and spleen, respectively, as determined by RT-PCR, [8] [9] [10] [11] [12] compared with age-matched controls (CON). A dashed horizontal line at 1.0 indicates relative miRNA-155 levels in control liver and spleen for ease of comparison (N = 5). *P < 0.01 (analysis of variance).
activation associated with autoimmunity and sustained inflammatory responses [9, 10, 19, 21, 22 ]. An extra copy of chromosome 21 might be expected to contribute to a 1.5fold increase in the expression of chromosome 21-encoded miRNAs; however, miRNA-155 levels were found to be increased 2.7-fold or more ( Fig. 1) . A recent, related study also shows miRNA-155 to be the most significantly upregulated chromosome 21-encoded miRNA in the prefrontal neocortex of adults with Down's syndrome [6] . This elevation may be due to intergenetic or epigenetic effects. Alternately, miRNA-155 is under the regulatory control of the transcription factor nuclear factor-kB, which is also upregulated in Down's syndrome tissues [7, 20, [22] [23] [24] [25] .
Although in this study only post-mortem tissues from female Down's syndrome patient's were examined, it will be interesting to analyze miRNA-155 and CFH levels in male and female, fetal and adolescent Down's syndrome samples to ascertain whether there are any effects of gender, development, or age. Although the miRNA-155-CFH mRNA-3 0 -UTR association is exceptionally stable, we cannot exclude the fact that other miRNA-155-mRNA interactions may also occur in vivo. Finally, CFH is significantly downregulated in Alzheimer's disease, predominantly by increased miRNA-146a. Interestingly, the miRNA-146a and miRNA-155 recognition features in the CFH mRNA 3 0 -UTR show partial overlap and binding site homology (Fig. 2 ) ( [9, [11] [12] [13] [14] [15] [16] [17] ; unpublished observations). For the first time these data suggest that two different brain miRNAs, miRNA-146a and miRNA-155, contribute to the downregulation of CFH expression in two different neurological disorders. As AM-155 significantly quenches induced miRNA-155 upregulation with restoration of CFH to homeostatic levels, targeting immunological signaling involved in Down's syndrome using AM-155 may reduce the susceptibility to inflammation and infections as typified by this tragic human disease.
Conclusion
Down's syndrome (trisomy 21), a congenital neurological disorder associated with immune deficits, progressive cognitive decline, and increased risk for early-onset Alzheimer's disease, is associated with the constitutive 5′ miRNA-155-complement factor H (CFH) complementarity map and schematic structure of the human CFH mRNA. Homosapiens micro RNA-155 (hsa-miRNA-155) (a) is a 23 nucleotide small RNA (highlighted in yellow) abundant in human brain and retinal and immune cells [8, 11, 16] , with a high predicted affinity for the CFH mRNA 3 0 -untranslated region (UTR) (highlighted in red). Ribonucleotides involved in fully (7) or partially (:) complementary hydrogen bonding are indicated. The predicted energy of association (E A ) for miRNA-mRNA interaction of -26.1 kcal/mol indicates strong intermolecular interaction [11, 12] . (b) Structural features of the CFH mRNA drawn to approximate scale indicating the relative sizes of the 5 0 leader sequence, coding region, the 232 nucleotide 3 0 -UTR, and poly-A tail. Dashed lines indicate the approximate location of miRNA-155 interaction within the 3 0 -UTR. Interestingly an miRNA-146a binding site in the CFH mRNA 3 0 -UTR, known to be important in CFH downregulation in Alzheimer's brain, partially overlaps with this miRNA-155 binding site ( [9, 11, 16] ; unpublished). overexpression of an extra copy of genes encoded on chromosome 21. In these studies, a chromosome 21q21encoded miRNA-155 was found to be significantly upregulated, more so than could be attributed to the chromosome 21 gene dosage effect alone, and a bioinformatics and experimentally confirmed miRNA-155 target, CFH mRNA, and CFH gene expression of this innate immune regulatory protein were found to be significantly downregulated in Down's syndrome tissues. 
